Application

18822148 · SINGLE-CHAIN TILAVONEMAB ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS

Filed 2024-08-31 · Pending The official file ↗ · Art unit 1647 · Examiner Audrey L Buttice Hard · CPC C07K 14/79 · RNA Therapeutics, Inc. · Sarfaraz K. Niazi

Office actions

first was

RCEs

no appeal

To first action

n/a

to disposition n/a

Statutes raised

0 actions read

Unlock the prosecution timelineIncluded in Pro, from $29 a month. Cancel any time.